Economic evaluation of donepezil treatment for Alzheimer's disease in Japan

Shunya Ikeda, Yukari Yamada, Naoki Ikegami

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

To demonstrate the economic impact of donepezil treatment for patients with mild to moderate Alzheimer's disease (AD) in Japanese clinical settings, we conducted a cost-utility analysis using the Markov model. This analysis was made from a payer's perspective, and the cost was estimated based on the fee schedule of the Japanese national health insurance and the long-term care insurance. The results of the clinical trial of donepezil on AD in Japan were used to estimate the drug efficacy. Under the base-case analysis with a 2-year time horizon, donepezil treatment for patients with mild to moderate AD was considered to be an economically dominant strategy compared to conventional therapy.

Original languageEnglish
Pages (from-to)33-39
Number of pages7
JournalDementia and Geriatric Cognitive Disorders
Volume13
Issue number1
DOIs
Publication statusPublished - 2002

Fingerprint

Cost-Benefit Analysis
Japan
Alzheimer Disease
Long-Term Care Insurance
Fee Schedules
National Health Programs
Therapeutics
Economics
Clinical Trials
Costs and Cost Analysis
Pharmaceutical Preparations
donepezil

Keywords

  • Alzheimer's disease
  • Donepezil
  • Economic evaluation, Cost-utility analysis
  • Quality-adjusted life years

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Geriatrics and Gerontology

Cite this

Economic evaluation of donepezil treatment for Alzheimer's disease in Japan. / Ikeda, Shunya; Yamada, Yukari; Ikegami, Naoki.

In: Dementia and Geriatric Cognitive Disorders, Vol. 13, No. 1, 2002, p. 33-39.

Research output: Contribution to journalArticle

Ikeda, Shunya ; Yamada, Yukari ; Ikegami, Naoki. / Economic evaluation of donepezil treatment for Alzheimer's disease in Japan. In: Dementia and Geriatric Cognitive Disorders. 2002 ; Vol. 13, No. 1. pp. 33-39.
@article{e991082532f84d7ab8ba5b5a6690398a,
title = "Economic evaluation of donepezil treatment for Alzheimer's disease in Japan",
abstract = "To demonstrate the economic impact of donepezil treatment for patients with mild to moderate Alzheimer's disease (AD) in Japanese clinical settings, we conducted a cost-utility analysis using the Markov model. This analysis was made from a payer's perspective, and the cost was estimated based on the fee schedule of the Japanese national health insurance and the long-term care insurance. The results of the clinical trial of donepezil on AD in Japan were used to estimate the drug efficacy. Under the base-case analysis with a 2-year time horizon, donepezil treatment for patients with mild to moderate AD was considered to be an economically dominant strategy compared to conventional therapy.",
keywords = "Alzheimer's disease, Donepezil, Economic evaluation, Cost-utility analysis, Quality-adjusted life years",
author = "Shunya Ikeda and Yukari Yamada and Naoki Ikegami",
year = "2002",
doi = "10.1159/000048631",
language = "English",
volume = "13",
pages = "33--39",
journal = "Dementia and Geriatric Cognitive Disorders",
issn = "1420-8008",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Economic evaluation of donepezil treatment for Alzheimer's disease in Japan

AU - Ikeda, Shunya

AU - Yamada, Yukari

AU - Ikegami, Naoki

PY - 2002

Y1 - 2002

N2 - To demonstrate the economic impact of donepezil treatment for patients with mild to moderate Alzheimer's disease (AD) in Japanese clinical settings, we conducted a cost-utility analysis using the Markov model. This analysis was made from a payer's perspective, and the cost was estimated based on the fee schedule of the Japanese national health insurance and the long-term care insurance. The results of the clinical trial of donepezil on AD in Japan were used to estimate the drug efficacy. Under the base-case analysis with a 2-year time horizon, donepezil treatment for patients with mild to moderate AD was considered to be an economically dominant strategy compared to conventional therapy.

AB - To demonstrate the economic impact of donepezil treatment for patients with mild to moderate Alzheimer's disease (AD) in Japanese clinical settings, we conducted a cost-utility analysis using the Markov model. This analysis was made from a payer's perspective, and the cost was estimated based on the fee schedule of the Japanese national health insurance and the long-term care insurance. The results of the clinical trial of donepezil on AD in Japan were used to estimate the drug efficacy. Under the base-case analysis with a 2-year time horizon, donepezil treatment for patients with mild to moderate AD was considered to be an economically dominant strategy compared to conventional therapy.

KW - Alzheimer's disease

KW - Donepezil

KW - Economic evaluation, Cost-utility analysis

KW - Quality-adjusted life years

UR - http://www.scopus.com/inward/record.url?scp=0036133542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036133542&partnerID=8YFLogxK

U2 - 10.1159/000048631

DO - 10.1159/000048631

M3 - Article

VL - 13

SP - 33

EP - 39

JO - Dementia and Geriatric Cognitive Disorders

JF - Dementia and Geriatric Cognitive Disorders

SN - 1420-8008

IS - 1

ER -